Methoxy- and Fluorine-Substituted Analogs of O-1302: Synthesis and in Vitro Binding Affinity for the CB1 Cannabinoid Receptor

The pentafluorosulfanyl group in cannabinoid receptor ligands: synthesis and comparison with trifluoromethyl and tert-butyl analogues

Competitive CB₁ receptor antagonists carrying an aromatic SF₅ group in position 3 of a pyrazole ring were synthesised and compared with their CF₃ and tert-butyl analogues. Results confirmed that an aromatic SF₅ group can be used as a bioisosteric analogue of a CF₃ group and possibly of a bulky aliphatic group too.

Development of PET radiopharmaceuticals and their clinical applications at the Positron Medical Center

The Positron Medical Center has developed a large number of radiopharmaceuticals and 36 radiopharmaceuticals have been approved for clinical use for studying aging and geriatric diseases, especially brain functions. Positron emission tomography (PET) has been used to provide a highly advanced PET-based diagnosis. The current status of the development of radiopharmaceuticals, and representative clinical and methodological results are reviewed.

A method for parallel solid-phase synthesis of iodinated analogues of the CB1 receptor inverse agonist rimonabant

A method for the parallel solid-phase synthesis (SPS) of iodinated analogues of Sanofi-Aventis' type 1 cannabinoid (CB1) receptor inverse agonist rimonabant (acomplia) has been developed. The method allows the synthesis of a range of C3 amide/hydrazide derivatives from a resin-bound C3 ester precursor. The C-Ge linkage to the Hypogel-200 resin is stable to the diversification conditions but allows ipso-iododegermylative cleavage using NaI/NCS even for the products containing the oxidatively labile hydrazide moiety.